INCY vs. RDY: Incyte vs. Dr. Reddy's Laboratories Stock Comparison

Company Profile

Incyte (INCY) and Dr. Reddy's Laboratories (RDY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while RDY is classified in Pharmaceuticals.

Incyte (INCY) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Incyte (INCY) at 7.84% and Dr. Reddy's Laboratories (RDY) at 7.34% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both Incyte (INCY) at 6.71% and Dr. Reddy's Laboratories (RDY) at 8.49% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Incyte (INCY) at 33.72% operates in the top operating margin quartile, ahead of Dr. Reddy's Laboratories (RDY) at 14.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Incyte (INCY) at 21.22% and Dr. Reddy's Laboratories (RDY) at 3.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Dr. Reddy's Laboratories (RDY) at -24.14%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Dr. Reddy's Laboratories (RDY) at 1.93 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RDY.

Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while Dr. Reddy's Laboratories (RDY) at 0.19 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a yield of 55.06%, ranking against industry peers normally.

Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a payout of 22.72%, ranking against industry peers normally.

Dividend Metrics

Valuation

Dr. Reddy's Laboratories (RDY) at 41.42 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Incyte (INCY) at 4.06 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

Incyte (INCY) at 4.33 sits near its industry’s typical P/B ratio, while Dr. Reddy's Laboratories (RDY) at 18.16 prices above its benchmark range — RDY looks rich relative to book.

Valuation Metrics